Key Stats for Danaher Stock
- YTD price change for Danaher stock Today: -18%
- $DHR Share Price as of Apr. 21: $195
- 52-Week High: $243
- $DHR Stock Price Target: $253
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Danaher (DHR) stock gained after the company reported Q1 2026 results that beat on both earnings and revenue.
- Adjusted EPS came in at $2.06, ahead of the $1.94 estimate.
- Revenue of $5.95 billion failed to meet the $5.98 billion forecast.
- Management raised full-year adjusted EPS guidance to $8.35 to $8.55, from the prior range of $8.35 to $8.50.
The top-line was driven by stronger-than-expected bioprocessing performance and better results in Life Sciences.
Bioprocessing consumables grew in the high single digits, supported by robust commercial biologic drug production.
More importantly, bioprocessing equipment orders grew more than 30% year-over-year, the first positive year-over-year equipment order growth in nearly two years. That signals a potential multi-year investment cycle is beginning to take shape.
See analysts’ growth forecasts and price targets for Danaher stock (It’s free) >>>
What the Market Is Telling Us About Danaher Stock
Danaher stock has been in a holding pattern as the company navigated several headwinds at once.
- China diagnostics pricing pressure, a lighter-than-usual respiratory season at Cepheid, and muted academic research spending all weighed on top-line growth, which came in at just 0.5% core revenue growth for the quarter.
- But the underlying trends are improving in meaningful ways.
- Outside of China and respiratory, the business grew at a mid-single-digit rate.
- Cepheid’s non-respiratory test menu grew in the mid-teens, led by sexual health and hospital-acquired infection assays.
- The new gastrointestinal panel is already seeing strong early customer wins. And
- Abcam, acquired a couple of years ago, is now generating both revenue growth and meaningful margin expansion thanks to the Danaher Business System.
The broader AI story is also a tailwind for Danaher stock over time. CEO Rainer Blair made a compelling case that AI will accelerate drug development pipeline yields, which in turn drives more investment in life science tools and bioprocessing.
In the near term, the company is already seeing incremental demand from what it calls “autonomous science,” which requires more automation, analytical instruments, and reagents, all areas where Danaher is well-positioned.
The pending Masimo acquisition adds another layer. Masimo brings mission-critical pulse oximetry and patient monitoring in acute care, complementing Danaher’s existing Radiometer business.
Management expects the deal to be accretive in year one and to reach high single-digit ROIC by year five.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Danaher Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
